ICCM — IceCure Medical Ltd.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1584371 · Israel
Last close
$3.65
Market Cap
$12.51M
52W High
$11.49
52W Low
$2.12
ADV30
6,824,201
Next earnings
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 911,000 295,000 -4,247,000 -4,274,000 13,303,000 8,115,000 4,809,000
Dec 2025 1,279,000 600,000 -4,216,000 -4,246,000 13,888,000 8,897,000 4,837,000
Sep 2025 850,000 277,000 -3,836,000 -3,859,000 15,078,000 4,971,000 5,772,000
Jun 2025 525,000 131,000 -3,385,000 -3,364,000 10,589,000 5,383,000 7,698,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,574,000
Investing CF
$-36,000
Financing CF
$15,834,000
CapEx
$-36,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.06
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-120,436,000
Inventory
$2,625,000
Receivables
$544,000
ST Investments
$5,034,000
EBIT TTM
$-15,094,000
Pretax Income TTM
$-15,057,000
Interest Exp TTM
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,565,000
EBITDA
$-15,409,000
Free Cash Flow
$-8,879,375
Enterprise Value
$2,550,336
Total Cash
$8,115,000
Total Debt
$139,000
Shares Out
3,426,375
Trailing EPS
$-7.20
Book Value
$3.14
ROE
-217.2%
ROA
-80.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 3,379,000 -15,094,000 -15,057,000 13,888,000 4,837,000 -14,574,000
Dec 2024 3,291,000 -15,696,000 -15,318,000 12,576,000 5,675,000 -12,563,000
Dec 2023 3,229,000 -15,576,000 -14,652,000 16,410,000 4,247,000 -12,550,000
Dec 2022 3,085,000 -16,739,000 -16,978,000 30,188,000 4,766,000 -14,292,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.51

Peers — same industry

TickerNameMarket CapLastDaily %
UEEC United Health Products, Inc. $12.63M $0.05
ADGM Adagio Medical Holdings, Inc. $12.66M $0.57
DROR Dror Ortho-Design, Inc. $12.70M $0.01
ZJYL Jin Medical International Ltd. $12.77M $1.87
ALRTF ALR Technologies SG Ltd. $12.91M $0.02

News headlines (Yahoo Finance, 1h cache)

IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
2026-07-06 12:11 · Yahoo
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-06-25 12:12 · Yahoo
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
2026-06-23 12:10 · Yahoo
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
2026-06-17 17:14 · Yahoo
ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?
2026-06-17 16:26 · Yahoo
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
2026-06-17 12:25 · Yahoo
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
2026-06-02 12:30 · Yahoo
Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and ...
2026-05-21 01:00 · Yahoo
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
2026-05-19 12:30 · Yahoo
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
2026-05-13 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.